Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. (Q52570231)

From Wikidata

Jump to navigation Jump to search

scientific article published on 23 April 2018

Language	Label	Description	Also known as
English	Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.	scientific article published on 23 April 2018

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas. (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

multicenter clinical trial

1 reference

based on heuristic

inferred from title

carboxyamidotriazole

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Xuling Lin

6

0 references

Cameron Brennan

object named as

Cameron W Brennan

25

0 references

22

object named as

Viviane Tabar

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

author name string

Antonio Omuro

1

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Kathryn Beal

2

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Katharine McNeill

3

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Robert J Young

4

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Alissa Thomas

5

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Robert Terziev

7

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Thomas J Kaley

8

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Lisa M DeAngelis

9

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Mariza Daras

10

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Igor T Gavrilovic

11

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Ingo Mellinghoff

12

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Eli L Diamond

13

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Andrew McKeown

14

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Malbora Manne

15

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Andrew Caterfino

16

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Krishna Patel

17

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Linda Bavisotto

18

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Greg Gorman

19

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Michael Lamson

20

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Philip Gutin

21

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Debyani Chakravarty

23

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Timothy A Chan

24

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Elizabeth Garrett-Mayer

26

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Rashida A Karmali

27

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Elena Pentsova

28

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

language of work or name

0 references

publication date

23 April 2018

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

JCO2017769992

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Targeting calcium signaling in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Carboxyamidotriazole inhibits oxidative phosphorylation in cancer cells and exerts synergistic anti-cancer effect with glycolysis inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Antiangiogenic therapy for glioblastoma: current status and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Emerging therapies for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

A randomized trial of bevacizumab for newly diagnosed glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Glioblastoma and other malignant gliomas: a clinical review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Retracted: Carboxyamidotriazole-Orotate Inhibits the Growth of Imatinib-Resistant Chronic Myeloid Leukaemia Cells and Modulates Exosomes-Stimulated Angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Selective sensitivity to carboxyamidotriazole by human tumor cell lines with DNA mismatch repair deficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Calcium and cancer: targeting Ca2+ transport

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Carboxyamido-triazole (CAI), a signal transduction inhibitor induces growth inhibition and apoptosis in bladder cancer cells by modulation of Bcl-2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Inhibitory effects of CAI in glioblastoma growth and invasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5993168

7 September 2018

Inhibition of pro-inflammatory cytokines in tumour associated macrophages is a potential anti-cancer mechanism of carboxyamidotriazole

1 reference

https://pubmed.ncbi.nlm.nih.gov/29683790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

OncoKB: A Precision Oncology Knowledge Base

1 reference

https://pubmed.ncbi.nlm.nih.gov/29683790

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2017.76.9992

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 May 2018

http://europepmc.org/abstract/MED/29683790

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52570231&oldid=2196480924"